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ABSTRACT 
Objective: To determine factors associated with continuous IV anesthetic drug (IVAD) use in 
nonconvulsive status epilepticus (NCSE). 
Methods: For this retrospective descriptive cohort study, we included all patients who met 
clinical and EEG criteria of NCSE from 2009 to 2014 at a tertiary academic medical center. 
Patients were categorized according to IVAD use. Primary outcome variables were response to 
treatment and in-hospital death. We used descriptive analyses for baseline characteristics, and 
primary and secondary outcome variables differences among patients who received IVAD and 
who did not receive IVAD. 
Results: Forty-three patients had a total of 45 NCSE episodes. IVAD was used in 69% of the 
episodes. Patients treated with IVAD were younger (53.1±14.1 vs 64.1±13.3, p=0.0187). The 
episodes treated with IVAD were associated with more acute neurologic pathology (58% vs 
21%, p=0.0236) and more commonly presenteded in comatose patients (39% vs 7%, p=0.0299). 
Underlying epilepsy was common in both groups (36% in IVAD vs 42% in no-IVAD group). 
NCSE resolved in 74% of the patients who received IVAD. There were total 13 in-hospital 
deaths (ten in IVAD users vs three in the no-IVAD group). Only one in-hospital death appeared 
to be a direct consequence of IVAD. 
Conclusion:  Our findings showed factors such as younger age, acute neurologic pathology and 
coma at presentation were associated with IVAD use in patients with NCSE. More patients died 
in IVAD group although this was not statistically significant. There is a need of further studies to 
determine the effect of IVAD use in NCSE on outcome, and these factors should be controlled in 
the future outcome and effectiveness studies. 
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INTRODUCTION 
Status epilepticus (SE), the continuous clinical and/or electrographic seizure activity 
lasting more than 5 minutes or recurrent seizures without recovery between the seizures 1, is a 
life threatening neurological emergency that requires immediate treatment. The incidence of SE 
varies between 9.9-41.0 per 100,000 population2–4 with a mortality rate of as high as 22% 3,5. 
There are two main subtypes of SE, convulsive SE (CSE) and nonconvulsive SE (NCSE), 
depending on the presence or absence of major motor signs. NCSE, in particular, is a 
heterogeneous medical condition with varying etiology and clinical presentation, including 
subtypes such as absence SE (ASE), simple partial SE, complex partial status epilepticus 
(CPSE), subtle SE (SSE), and NCSE in coma. NCSE has been reported in up to 27% of ICU 
patients with altered mental status, 8% of those in coma, and 34% of status epilepticus (SE). In 
these patients, NCSE is associated with excess risk for morbidity and mortality 6–8. Its mortality 
risk is associated with the underlying etiology, with higher rates noted in patients with an acute 
medical condition and acute brain injury, and lower rates in patients with a previous known 
history of epilepsy, CPSE and ASE 9–11 .  
First line treatment of SE generally starts with lorazepam as recommended by the 
Veteran’s Administration trial 12 or with other benzodiazepines such as midazolam, or diazepam 
and continues with an anticonvulsant such as phenytoin or fosphenytoin, valproate sodium, or 
phenorbarbital. If SE continues,  the Neurocritical Care Society and European Federation of 
Neurological Societies guidelines recommend continuous infusion of an IV anesthetic drug 
(IVAD) such as midazolam, propofol, pentobarbital, or thiopental, to achieve burst-suppression 
13,14. The guidelines note, however, that little data is available to direct continuing therapy for 
refractory SE  
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The dearth of evidence is even more apparent for refractory NCSE. Guidelines cautiously  
recommend use of IVAD and recommendcommend tailoring the treatment to the individual 
patient and using further non anesthetic anticonvulsants before IVAD due to the potential for  
favorable outcomes with CPSE and the other known risks of IVAD 14–16.  
There is a dearth of data in the literature detailing how IVAD is used in NCSE 
management. This limits our understanding of the association between IVAD use and patient 
outcomes. Although recent reports suggest an increased risk of poor outcomes with use of IVAD 
in SE, more research specific to NCSE is needed 17–19. In addition, identification of potential 
confounders, such as underlying etiology or co-morbidities in relation to IVAD use, is needed. 
Therefore, we characterized our center’s management of a cohort of NCSE patients to identify 
the clinical context, outcomes and factors associated with IVAD use in order to support further 
outcome and effectiveness studies and to determine if IVAD use is associated with higher 
mortality rate.  
 
MATERIAL AND METHODS 
Setting and Design. We performed a retrospective cohort study of patients with NCSE at the 
University of Kansas Medical Center, Kansas City, KS, a tertiary academic medical care center. 
The study was approved by the Institutional Review Board. 
Case Identification. To provide the initial sample, we reviewed electronic medical records of 
patients admitted and treated between January 1st, 2009 through June 30th, 2014 who had 
undergone an EEG (with at least daily follow-up EEG) and/or continuous-video EEG (cvEEG), 
and had one or more of the following ICD-9 diagnosis codes for SE (345.2, 345.3) or epilepsia 
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partialis continua (345.70, 345.71). Inclusion criteria were those patient who met both the 
clinical definition of NCSE and who met EEG criteria. The clinical definition of NCSE was ”a 
range of conditions in which electrographic seizure activity is prolonged and results in 
nonconvulsive clinical symptoms.”20. The onset of NCSE was determined as the onset of clear 
clinical change in the neurologic condition even before the first EEG. EEG criteria are shown in 
Table 121. Exclusion criteria were: 1) lack of or insufficient EEG or cvEEG to confirm the 
diagnosis, 2) simple partial status epilepticus, 3) poor clinical documentation on findings at 
presentation, 4) diagnosis of Creutzfeldt-Jacob disease, and 5) anoxic brain injury at 
presentation. We excluded patients with anoxic brain injury because of the uncertainty about the 
epileptic nature of status myoclonus and its independent association with poor outcomes 22–25. 
Treatment of NCSE was left to the discretion of the attending epileptologists and 
neurointensivists.  
 
Table 1. Working clinical criteria for nonconvulsive status epilepticus. Adapted from 
Beniczky et al21. 
Working criteria for nonconvulsive status epilepticus 
Patients without known epileptic encephalopathy 
   Epileptiform discharges with a frequency > 2.5 Hz, or 
    Epileptiform discharges with a frequency ≤ 2.5 Hz or rhythmic delta/theta activity (>0.5 Hz) 
and one of the following: 
       EEG and clinical improvement after iv anticonvulsant, or 
       Subtle clinical ictal phenomena during the EEG patterns mentioned above, or 
       Typical spatiotemporal evolution (change in voltage and frequency or location) 
Patients with known epileptic encephalopathy 
       Increase in prominence or frequency of the features mentioned above, when compared to 
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baseline with observable change in clinical state 
      Improvement of clinical and EEG features with iv anticonvulsant 
 
Data Collection and Variables. We extracted data from electronic medical records.Variables 
included demographics and clinical symptoms at the time of admission: level of consciousness at 
the onset of NCSE, presence of subtle motor findings (gaze or head deviation, rhythmic 
twitching of facial, ocular or extremity muscles), presence of GTC at the onset, co-morbidities, 
history of epilepsy, underlying etiology (individual diagnosis and acute medical pathology or 
acute neurologic pathology), sepsis at the time of diagnosis, presence of coma or intubation 
status. Acute neurologic pathology was defined as presence of meningoencephalitis, brain tumor, 
white matter changes, hypoxic-ischemic, metabolic or pharmacologic encephalopathy and stroke. 
Acute medical pathology was defined as presence of underlying infection, trauma other than 
traumatic brain injury, recent surgery before NCSE, or organ or system problem other than CNS 
were classified as having an acute medical condition.  
We used the Status Epilepticus Severity Score (STESS) to grade the severity of NCSE. 
This score was calculated based on consciousness (alert or somnolent=0, stuporous/comatose=1), 
worst seizure type (simple partial, complex partial, absence or absence seizures=0, generalized 
convulsive seizures=1, NCSE in coma=2), age (<65 years=0, ≥65 years=1), and history of 
previous seizures (yes=0, no or unknown=1) and is dichotomized asas favorable (0-2) and 
unfavorable (3-6) to predict death as proposed by Rosetti et al 26.  
We classified the antiepileptic treatment as a benzodiazepine (BZD) for the initial dose of 
IV lorazepam, IV/IM/rectal diazepam, or IV/intranasal midazolam; as intravenous non-anesthetic 
AED for IV phenytoin/fosphenytoin, valproate sodium, phenobarbital, levetiracetam or 
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lacosamide; as IVAD for continuous IV infusion of midazolam, propofol, pentobarbital, 
thiopental, or ketamine to achieve burst-suppression. If the patient was already on IVAD for 
other reasons, we did not count this as antiepileptic treatment unless IVAD dose was modified to 
treat NCSE to achieve burst-suppression. 
Primary and secondary outcomes. Our primary outcome variables were response to treatment 
and in-hospital death. Our secondary outcomes were used for exploratory analysis and included 
first choice treatment and use of more than one AED. Response to treatment was categorized as 
no response or resolution of NCSE with resolution ascertained by clinical improvement and/or 
EEG findings. We defined time to resolution as the number of days between the clinical and 
electroencephalographic diagnosis of NCSE and their clinical and/or electroencephalographic 
resolution of NCSE. We reported days as more exact time parameters were not consistently 
available. Temporary improvement was defined as either transient stopping of subtle motor 
movements or improvement in mental status without complete resolution of clinical findings, or 
temporary decrease in number or duration of electrographic seizures, fragmentation of rhythmic 
activity or decreased duration of rhythmic discharges with emergence of background in between.  
Statistical analysis. All results were limited to descriptive analyses due to the small sample size. 
We compared primary and secondary variables among patients who received IVAD and who did 
not receive IVAD. We applied the Shapiro-Wilk test for continuous variables to assess normal 
distribution. Categorical variables were compared by Fisher exact test and continuous variables 
by t-tests if the data were distributed normally and Mann-Whitney U test if data were non-
normal.  
 
RESULTS 
5 
 
Using the electronic medical record, we identified 188 episodes treated between January 1st, 
2009 and June 30th, 2014. Forty-three patients met study criteria. Two patients had two episodes 
of NCSE for total of 45 NCSE episodes (Figure 1). 
 
Figure 1. Sample identification and treatment responses of the NCSE episodes 
 
NCSE= Noncounvulsive status epilepticus, ivAED= iv non-anesthetic antiepileptic drug, BZD= 
benzodiazepine, IVAD=iv anesthetic drug. 
Demographics and baseline clinical characteristics. Of the 45 NCSE episodes, 69% were 
treated with IVAD (Table 2). Patients treated with IVAD were younger. The episodes treated 
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with IVAD were associated with more acute neurologic pathology, higher STESS score, and 
more common in patients who were comatose. IVAD was used more commonly to treat NCSE 
when the patient was already intubated.  
 In seventeen episodes (38%) patients had history of epilepsy. The most common 
presenting symptom was AMS with subtle motor symptoms without preceding GTCS. Only 29% 
of the NCSE episodes had preceding GTCS with no recovery in mental status afterwards. About 
18% of the NCSE episodes were associated with coma, and 47% had an underlying acute 
neurologic pathology.  
 
Table 2. Demographics and clinical characteristics. 
 Whole Group No IVAD IVAD p-value 
Number of patients  43 14 29  
  Age  56.7±14.7 64.1±13.3 53.1±14.1 0.0187* 
  Sex-Male  20 (46.5%) 6 (42.9%) 14 (48.3%) NS 
Number of NCSE episodes  45 14 31  
Symptom at onset     
  AMS only  12 (26.7%) 5 (35.7%) 7 (22.6%) NS 
  AMS/subtle motor findings 20 (44.4%) 5 (35.7%) 15 (48.4%) NS 
  AMS following GTCS  9 (20.0%) 3 (21.4%) 6 (19.3%) NS 
  AMS/subtle motor finding following  GTCS  4 (8.9%) 1 (7.1%) 3 (9.7%) NS 
Epilepsy 17 (37.8%) 6 (42.9%) 11 (35.5%) NS 
Acute Medical Pathology 26 (57.8%) 8 (57.1%) 18 (58.1%) NS 
Acute Neurologic Pathology 21(46.7%) 3 (21.4%) 18 (58.1%) 0.0236* 
STESS ≥3 (Status severity score) 23 (51.1%) 6 (42.9%) 17 (54.8%) NS 
Coma 8 (17.8%) 0 (0%) 8 (25.8%) 0.0366* 
Already intubated before NCSE  13 (28.9%) 1 (7.1%) 12 (38.7%) 0.0299* 
IVAD=iv anesthetic drug, AMS= Altered mental status, GTCS= Generalized tonic-clonic 
seizure, STESS= Status Epilepticus Severity Score. 
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Etiology. Out of 17 NCSE episodes in patients with a history of epilepsy, five were due to 
medication non-compliance, two were due to sepsis, and two were due to other infections (Table 
3). In the remaining episodes, infection caused seven and intracranial hemorrhage caused five 
episodes. Medication-induced NCSE occurred in four episodes (three from tacrolimus and one 
from cefepime), meningoencephalitis in four episodes, autoimmune encephalitis in two episodes, 
and ischemic stroke in two episodes. Trauma, meningioma, metabolic abnormality, and Non 
Hodgkin Lymphoma with leptomeningeal involvement caused NCSE in one episode. Sepsis with 
or without history of epilepsy, ICH, and meningoencephalitis were more common etiologies in 
episodes treated with IVAD. 
 
Table 3. Etiology of nonconvulsive status epilepticus 
Etiology Whole Group No IVAD  IVAD  
Epilepsy (total) 17 (37.8%) 6 (42.8%) 11 (35.5%) 
    Epilepsy-medication noncompliance  5 (11.1%) 2 (14.3%)  3 (9.7%) 
    Epilepsy-sepsis  2 (4.4%) 0 (0.0%)  2 (6.45%) 
    Epilepsy-infection  2 (4.4%) 0 (0.0%)  2 (6.45%) 
Infection (excluding cases with epilepsy)  7 (15.5%) 2 (14.3%)  5 (16.1%) 
    Sepsis  5 (11.1%) 1 (7.1%)  4 (12.9%) 
    Infection-no sepsis  2 (4.4%) 1 (7.1%)  1 (3.2%) 
Intracranial hemorrhage  5 (11.1%) 1 (7.1%)  4 (12.9%) 
Medication  4 (8.9%) 2 (14.3%)  2 (6.4%) 
Meningoencephalitis  4 (8.9%) 0 (0.0%)  4 (12.9%) 
Autoimmune encephalitis  2 (4.4%) 1 (7.1%)  1 (3.2%) 
Stroke  2 (4.4%) 0 (0.0%)   2 (6.4%) 
Trauma  1 (2.2%) 0 (0.0%)  1 (3.2%) 
Non Hodgkin Lymphoma  1 (2.2%) 1 (7.1%)  0 (0.0%) 
Meningioma 1 (2.2%) 0 (0.0%) 1 (3.2%) 
Metabolic 1 (2.2%) 1 (7.1%) 0 (0.0%) 
IVAD=iv anesthetic drug, CNS= Central nervous system., IVAD=iv anesthetic drug. 
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Treatment. BZDs were used in 27 (60%) episodes as first choice (Figure 22). In 11 episodes it 
was given before the EEG – three in outside hospital before transfer- and in 16 episodes during 
the EEG. In both groups majority of the episodes were treated with BZD as first-line treatment; 
nine episodes (64%) in no IVAD and 18 episodes (58%) in IVAD group. A non-sedating 
intravenous AED was first choice in nine (29%) episodes in IVAD group and in five episodes 
(36%) in no IVAD group. In all episodes when IVAD was used patients were intubated, whereas 
patients were intubated in only two episodes (14%) for airway protection when IVAD was not 
used. Only in four episodes with already intubated patients was IVAD started to treat NCSE 
before use of BZD or intravenous AED. Intravenous AED was used in all of the NCSE episodes. 
In 68% of episodes treated with IVAD and in 79% of episodes treated with no IVAD, patients 
had additional non-anesthetic intravenous AED.  
 
Figure 2. Distribution of medications administered to stop NCSE stratified by use of IVAD 
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IV AED= iv non-anesthetic antiepileptic drug, BZD= benzodiazepine, IVAD=iv anesthetic drug. 
 
Out of 31 episodes treated with IVAD, 11 episodes (36%) required more than one IVAD. 
Propofol was used in total 24 episodes; in 19 episodes as first choice, in 12 episodes as only 
IVAD and in five episodes as the second choice. Midazolam was used in 21 episodes; in 11 
episodes as first choice, in six episodes as only IVAD and in eight episodes as second or third 
choice. Pentobarbital is used in four episodes but only in one episode as first choice. Ketamine 
was used in three episodes as second and third choice. 
Outcomes. Of 45 NCSE episodes, 9 (20%) did not respond to treatment. Among those who did 
not respond to treatment, one patient’s family denied further care after the diagnosis of NCSE; in 
eight episodes burst-suppression pattern was achieved, but seven patients expired; and one 
patient was sent to hospice. Of 27 episodes treated with BZD as first choice, two episodes (4%) 
showed resolution and nine episodes (20%) showed temporary clinical or EEG improvement. 
BZD and intravenous AED together appeared to lead to resolution of NCSE in 18% of the 
episodes. About 50% of NCSE appeared to respond to IVAD. Among patients who were treated 
with IVAD, 74% of the NCSE episodes resolved after initiation of IVAD (Table 4). 
 
Table 4. Outcome variables 
 Whole Group No IVAD IVAD p-value 
Resolution of NCSE     
    No resolution 9 (20.0%) 1 (7.14%)  8 (25.8%) NS 
    With BZD only    2 (4.4%) 2 (14.3%) NA  
    With ivAED only    3 (6.7%) 3 (21.4%) NA  
    With BZD+ivAED 8 (17.8%) 8 (57.1%) NA  
    With ivAED+IVAD 9 (20.0%) NA  9 (29.3%)  
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    BZD+ivAED+IVAD 14 (31.1%) NA 14 (45.2%)  
Time to resolution sincefrom NCSE diagnosis     
     Median (Days) 1 1 1 NS 
     Mean (Days) 2.0±2.1 1.5±1.1 2.4±2.5 NS 
In-hospital death 13 (28.9%) 3 (21.4%) 10 (32.3%) NS 
ivAED= iv non-anesthetic antiepileptic drug, BZD= benzodiazepine, IVAD=iv anesthetic drug. 
 
There were total 13 in-hospital deaths, ten in the IVAD group and three in patientspatient 
without IVAD group (Table 5). All patients but two had potentially fatal medical conditions.  
Among patients on IVAD, one patient who had epilepsy died from propofol infusion syndrome. 
This patient also met the sepsis criteria after starting IVAD. Four patients died from sepsis, three 
of whom had either sepsis or infection at the admission. The rest of the patients died due to 
worsening of their underlying medical conditions or complications. All three patients who died 
in no IVAD group were also very sick with multiple medical problems. In one of them, the 
family denied further care.  The second had  pneumonia, pancytopenia, progressive multifocal 
leukoencephalopathy and graft versus host disease.  The third had Non-Hodgkin lymphoma with 
leptomeningeal involvement.  
 
 
Table 5. Etiology and EEG findings of the patients who died in the hospital 
Patient Reason for death Etiology of NCSE EEG finding at 
the time of death 
 
IVAD     
  1 Multi organ dysfunction Meningoencephalitis NCSE-BS-NCSE  
  2 Meningoencephalitis Meningoencephalitis Diffuse slowing  
  3 NCSE Meningoencephalitis NCSE-BS-NCSE  
  4 Sepsis Stroke BS  
  5 Sepsis Sepsis BS  
  6 Stroke Ruptured thoracic aortic 
aneurysm 
Diffuse slowing  
  7 Sepsis Epilepsy/ Urinary tract 
infection 
BS  
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  8 Sepsis Sepsis NCSE  
  9 Intracranial hemorrhage/ischemic 
stroke 
Intracranial hemorrhage Diffuse slow  
 10 Propofol infusion syndrome/sepsis Epilepsy BS  
 
No 
IVAD 
    
 11 Sepsis, NCSE (family denied 
further care) 
Sepsis NCSE   
 12 Non Hodgkin Lymphoma/ 
Leptomeningeal involvement 
Non Hodgkin Lymphoma/ 
Leptomeningeal involvement  
Diffuse slowing 
 
 
 13 Progressive multifocal 
leukoencephalopathy, graft versus 
host disease 
Infection Diffuse 
slowing/GPD 
 
Death= In-hospital death, NCSE= Noncounvulsive status epilepticus, BS= burst-suppression, 
GPD=generalized periodic discharges. 
 
 
DISCUSSION 
In this retrospective single center cohort study, we analyzed 45 rigorously defined NCSE 
episodes from 43 patients to evaluate the clinical contexts and outcomes of IVAD use. The 
majority of the NCSE episodes (69%) at our institution were treated with IVAD. Those who 
were treated with IVAD were younger in age, had an acute neurologic pathology, and had been 
in a coma or intubated. The majority of the patients, regardless of ongoing IVAD use, received 
BZD as first choice treatment, and 100% in the no IVAD group and 87% of IVAD group 
received either BZD or an intravenous non-sedating AED as first choice of treatment showing 
compliance with published guidelines in general. NCSE resolved in 74% of the patients who 
received IVAD, though in-hospital death, and sepsis was more common among the IVAD group.  
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One of our most striking findings was the high rate of IVAD use. We found that 69% of 
the NCSE episodes treated in our center received IVAD. While this rate appears higher than 
previous reports of 11% to 37%, we restricted our cohort to persons with NCSE while others 
included NCSE as a subtype among other SE types17,27 . The higher rate in our cohort may also 
reflect the selection of more refractory cases as we required ongoing EEG evidence of seizure. 
Higher rates of IVAD use have been reported in patients with refractory SE. For instance, 
Hocker et al showed that 87.3% of their refractory SE of any type received IVAD28. However, 
Novy et al reported only 30% their refractory NCSE received IVAD29.  They attributed their low 
rate to their practice of escalating the use of non-sedating AEDs and monitoring response before 
considering IVAD use. In our cohort we noted that the majority of episodes were treated with 
additional intravenous non-sedating AED whether IVAD was used or not.  Given the dearth of 
research on practice patterns in NCSE management, further examination of treatment 
implementation across other academic medical centers would better establish the state of the art 
for refractory NCSE. 
One of our aims was to describe factors associated with IVAD use in NCSE. We found 
that IVAD use was more frequent in episodes when the patients were younger, had an acute 
neurological pathology as etiology, and were in a coma or already intubated before the NCSE 
diagnosis. In our cohort, the proportion of those treated with IVAD who had severe status 
(STESS ≥3) was higher than those who did not get IVAD, though the difference was not 
statistically significant.  Whether these factors are associated with refractoriness in NCSE cannot 
be answered by our study. However, a recent study identified acute etiology, coma/stupor, and 
decreased serum albumin as early predictors of refractory status epilepticus 30. We appreciate 
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that a direct comparison between their study and ours cannot be made due to methodological 
differences, but about 70% of their cohort had NCSE indicating important similarities.  
Our findings showed in general that patients treated with IVAD were sicker and had more 
acute CNS insult, both of which can be confounders for the higher mortality rate in these 
patients. Whether patients treated with IVAD had better or worse outcome than patients with 
same etiology of epileptic injury or same severity of brain injury is not known. We believe that 
the establishment of multicenter consortiums may enable the accruement of larger cohorts to 
control for severity and etiology. From previous reports we know that acute neurologic 
pathology is associated with both refractoriness, high mortality and poor outcome in both in SE 
and NCSE 10,18,30. Severe consciousness impairment was also independently associated with 
refractoriness29. Patients who are in a coma or intubated are expected to have higher risk of 
dying from their underlying medical condition. Similarly, how much age would account for poor 
outcomes is not very well established. For example, in previous reports patients treated with 
IVAD were younger than the others, but older age was associated with poor outcomes in patients 
treated with IVAD17,18,31. Whether younger patients are more appropriate for aggressive 
treatment by the treating physician needs to be addressed in this patient population. We did not 
find any difference between two groups regarding the duration of symptoms from onset till 
diagnosis or duration of NCSE from the diagnosis till resolution in patients who responded to the 
treatment. This may imply by the time the EEG is obtained, NCSE may have resolved. Although 
in patients with prolonged SE, the outcome is reported to be worse, neither total duration of SE 
nor SE >10 hours is shown to bea reliable predictor of poor outcomes32,33.  
In our study we found about 74% of the NCSE resolved in IVAD group. In all but four 
episodes where IVAD was first choice of treatment, IVAD was used when NCSE did not resolve 
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with BZD or non-sedating intravenous AED.  However, thirty-five percent of the patients 
required more than one IVAD with an initial response of 63% to propofol and 54% to 
midazolam. Similar findings were reported previously in refractory SE patients. In their review 
Claassen et al. reported acute treatment failure rates for IVADs: midazolam (23%), propofol 
(32%), and pentobarbital (20%)33. Breakthrough seizures were more common with midazolam. 
Including other types of SE, they found lower failure and breakthrough seizures with 
pentobarbital but hypotension requiring vasopressors was more common with pentobarbital. In a 
randomized study comparing barbiturates to propofol, however, initial response rate to treatment 
was higher with propofol. Nevertheless, overall response with subsequent treatment in both 
groups was high34.  
Recent retrospective studies have shown that use of IVAD is associated with poor 
outcome17,18,27, though their methods had inadequate control for confounders and their findings 
cannot be generalized to NCSE due to involvement of other types of SE in their patient 
population. Ten patients died in our IVAD group whereas only three patients died in the group 
where patients did not receive IVAD, though this difference was not statistically significant. 
When we look at these 10 patients, only one in-hospital death could be attributed to propofol 
infusion syndrome as a direct consequence of IVAD. Four of the other nine patients had sepsis, 
in two of whom NCSE was due to sepsis making the IVAD less likely the cause of in-hospital 
death. This comment should be interpreted very cautiously because worsening of the ongoing 
sepsis or additional problems due to IVAD could not be excluded. It is debatable whether NCSE 
is directly associated with higher mortality rates or poor cognitive and neurologic outcomes, 
although it is known that NCSE is associated with refractoriness35,36. Nevertheless, there is a 
need to address this ongoing debate with further studies that isolate the effectiveness of IVAD in 
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refractory NCSE37,38. While a randomized controlled trial including only NCSE would be the 
best method to assess the effect of IVAD on the outcome, this would undoubtedly be difficult 
given feasibility concerns, with respect to low recruitment rates and subtleties of the clinical 
course of NCSE34. A large, multi-center, prospective observational study that adjusts for 
confounding across multiple factors such as age, acute neurologic pathology, and presence of 
coma or intubation at baseline may well provide the best option to study NCSEN management.  
Our study has certain limitations. First, we used a retrospective cohort design with data 
collected from chart review within a single academic medical setting. This poses important 
selection issues mainly regarding the onset and duration of NCSE. Second, we were only able to 
determine the duration of in-house NCSE in EEG as days as opposed to hours, partly due to 
inadequate archiving of EEG traces and insufficient documentation in the chart. Choice of 
treatment was based on discretion of treating physician leading to significant issues of treatment 
selection bias. Nevertheless we consider that this variability reflects real world practice and 
actually may be one of the strengths of the study. Third, our small sample size precluded 
statistical adjustments to examine the associations between several variables and IVAD use and 
subsequent outcomes. Fourth, by using strict EEG criteria we might underestimate the 
denominator of NCSE by potentially excluding NCSE cases that met clinical criteria but 
resolved before EEG was obtained. However, this way we have confirmed NCSE patients which 
would be potential catchment population for future studies. 
In summary, our study contributes to sparse literature about the IVAD use in SE by 
evaluating patients only with NCSE. We have shown that factors such as age, acute neurologic 
pathology, and baseline coma and intubation status are more common in NCSE episodes treated 
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with IVAD. More patients died in IVAD group although this was not statistically significant. 
Further studies are needed to determine the effect of IVAD use in NCSE on outcome.  
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